A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge

Yfat Yahalom-Ronen; Hadas Tamir; Sharon Melamed; Boaz Politi; Ohad Shifman; Hagit Achdout; Einat B. Vitner; Ofir Israeli; Elad Milrot; Dana Stein; Inbar Cohen-Gihon; Shlomi Lazar; Hila Gutman; Itai Glinert; Lilach Cherry; Yaron Vagima; Shirley Lazar; Shay Weiss; Amir Ben-Shmuel; Roy Avraham; Reut Puni; Edith Lupu; Elad Bar-David; Assa Sittner; Noam Erez; Ran Zichel; Emanuelle Mamroud; Ohad Mazor; Haim Levy; Orly Laskar; Shmuel Yitzhaki; Shmuel C. Shapira; Anat Zvi; Adi Beth-Din; Nir Paran; Tomer Israely

doi:10.1038/s41467-020-20228-7

A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge

Yfat Yahalom-Ronen
, Hadas Tamir
, Sharon Melamed
, Boaz Politi
, Ohad Shifman
, Hagit Achdout
, Einat B. Vitner
, Ofir Israeli
, Elad Milrot
, Dana Stein
, Inbar Cohen-Gihon
, Shlomi Lazar
, Hila Gutman
, Itai Glinert
, Lilach Cherry
, Yaron Vagima
, Shirley Lazar
, Shay Weiss
, Amir Ben-Shmuel
, Roy Avraham

Reut Puni, Edith Lupu, Elad Bar-David, Assa Sittner, Noam Erez, Ran Zichel, Emanuelle Mamroud, Ohad Mazor, Haim Levy, Orly Laskar, Shmuel Yitzhaki, Shmuel C. Shapira, Anat Zvi, Adi Beth-Din, Nir Paran, Tomer Israely

Research output: Contribution to journal › Article › peer-review

184 Scopus citations

Abstract

The COVID-19 pandemic caused by SARS-CoV-2 imposes an urgent need for rapid development of an efficient and cost-effective vaccine, suitable for mass immunization. Here, we show the development of a replication competent recombinant VSV-∆G-spike vaccine, in which the glycoprotein of VSV is replaced by the spike protein of SARS-CoV-2. In-vitro characterization of this vaccine indicates the expression and presentation of the spike protein on the viral membrane with antigenic similarity to SARS-CoV-2. A golden Syrian hamster in-vivo model for COVID-19 is implemented. We show that a single-dose vaccination results in a rapid and potent induction of SARS-CoV-2 neutralizing antibodies. Importantly, vaccination protects hamsters against SARS-CoV-2 challenge, as demonstrated by the abrogation of body weight loss, and alleviation of the extensive tissue damage and viral loads in lungs and nasal turbinates. Taken together, we suggest the recombinant VSV-∆G-spike as a safe, efficacious and protective vaccine against SARS-CoV-2.

Original language	English
Article number	6402
Journal	Nature Communications
Volume	11
Issue number	1
DOIs	https://doi.org/10.1038/s41467-020-20228-7
State	Published - 1 Dec 2020
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

General Chemistry
General Biochemistry, Genetics and Molecular Biology
General
General Physics and Astronomy

Access to Document

10.1038/s41467-020-20228-7

Cite this

Yahalom-Ronen, Y., Tamir, H., Melamed, S., Politi, B., Shifman, O., Achdout, H., Vitner, E. B., Israeli, O., Milrot, E., Stein, D., Cohen-Gihon, I., Lazar, S., Gutman, H., Glinert, I., Cherry, L., Vagima, Y., Lazar, S., Weiss, S., Ben-Shmuel, A., ... Israely, T. (2020). A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge. Nature Communications , 11(1), Article 6402. https://doi.org/10.1038/s41467-020-20228-7

@article{1331a40fb92946de8dd5201dc84294bd,

title = "A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge",

abstract = "The COVID-19 pandemic caused by SARS-CoV-2 imposes an urgent need for rapid development of an efficient and cost-effective vaccine, suitable for mass immunization. Here, we show the development of a replication competent recombinant VSV-∆G-spike vaccine, in which the glycoprotein of VSV is replaced by the spike protein of SARS-CoV-2. In-vitro characterization of this vaccine indicates the expression and presentation of the spike protein on the viral membrane with antigenic similarity to SARS-CoV-2. A golden Syrian hamster in-vivo model for COVID-19 is implemented. We show that a single-dose vaccination results in a rapid and potent induction of SARS-CoV-2 neutralizing antibodies. Importantly, vaccination protects hamsters against SARS-CoV-2 challenge, as demonstrated by the abrogation of body weight loss, and alleviation of the extensive tissue damage and viral loads in lungs and nasal turbinates. Taken together, we suggest the recombinant VSV-∆G-spike as a safe, efficacious and protective vaccine against SARS-CoV-2.",

author = "Yfat Yahalom-Ronen and Hadas Tamir and Sharon Melamed and Boaz Politi and Ohad Shifman and Hagit Achdout and Vitner, \{Einat B.\} and Ofir Israeli and Elad Milrot and Dana Stein and Inbar Cohen-Gihon and Shlomi Lazar and Hila Gutman and Itai Glinert and Lilach Cherry and Yaron Vagima and Shirley Lazar and Shay Weiss and Amir Ben-Shmuel and Roy Avraham and Reut Puni and Edith Lupu and Elad Bar-David and Assa Sittner and Noam Erez and Ran Zichel and Emanuelle Mamroud and Ohad Mazor and Haim Levy and Orly Laskar and Shmuel Yitzhaki and Shapira, \{Shmuel C.\} and Anat Zvi and Adi Beth-Din and Nir Paran and Tomer Israely",

note = "Publisher Copyright: {\textcopyright} 2020, The Author(s).",

year = "2020",

month = dec,

day = "1",

doi = "10.1038/s41467-020-20228-7",

language = "English",

volume = "11",

journal = "Nature Communications ",

issn = "2041-1723",

number = "1",

}

Yahalom-Ronen, Y, Tamir, H, Melamed, S, Politi, B, Shifman, O, Achdout, H, Vitner, EB, Israeli, O, Milrot, E, Stein, D, Cohen-Gihon, I, Lazar, S, Gutman, H, Glinert, I, Cherry, L, Vagima, Y, Lazar, S, Weiss, S, Ben-Shmuel, A, Avraham, R, Puni, R, Lupu, E, Bar-David, E, Sittner, A, Erez, N, Zichel, R, Mamroud, E, Mazor, O, Levy, H, Laskar, O, Yitzhaki, S, Shapira, SC, Zvi, A, Beth-Din, A, Paran, N & Israely, T 2020, 'A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge', Nature Communications , vol. 11, no. 1, 6402. https://doi.org/10.1038/s41467-020-20228-7

TY - JOUR

T1 - A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge

AU - Yahalom-Ronen, Yfat

AU - Tamir, Hadas

AU - Melamed, Sharon

AU - Politi, Boaz

AU - Shifman, Ohad

AU - Achdout, Hagit

AU - Vitner, Einat B.

AU - Israeli, Ofir

AU - Milrot, Elad

AU - Stein, Dana

AU - Cohen-Gihon, Inbar

AU - Lazar, Shlomi

AU - Gutman, Hila

AU - Glinert, Itai

AU - Cherry, Lilach

AU - Vagima, Yaron

AU - Lazar, Shirley

AU - Weiss, Shay

AU - Ben-Shmuel, Amir

AU - Avraham, Roy

AU - Puni, Reut

AU - Lupu, Edith

AU - Bar-David, Elad

AU - Sittner, Assa

AU - Erez, Noam

AU - Zichel, Ran

AU - Mamroud, Emanuelle

AU - Mazor, Ohad

AU - Levy, Haim

AU - Laskar, Orly

AU - Yitzhaki, Shmuel

AU - Shapira, Shmuel C.

AU - Zvi, Anat

AU - Beth-Din, Adi

AU - Paran, Nir

AU - Israely, Tomer

PY - 2020/12/1

Y1 - 2020/12/1

N2 - The COVID-19 pandemic caused by SARS-CoV-2 imposes an urgent need for rapid development of an efficient and cost-effective vaccine, suitable for mass immunization. Here, we show the development of a replication competent recombinant VSV-∆G-spike vaccine, in which the glycoprotein of VSV is replaced by the spike protein of SARS-CoV-2. In-vitro characterization of this vaccine indicates the expression and presentation of the spike protein on the viral membrane with antigenic similarity to SARS-CoV-2. A golden Syrian hamster in-vivo model for COVID-19 is implemented. We show that a single-dose vaccination results in a rapid and potent induction of SARS-CoV-2 neutralizing antibodies. Importantly, vaccination protects hamsters against SARS-CoV-2 challenge, as demonstrated by the abrogation of body weight loss, and alleviation of the extensive tissue damage and viral loads in lungs and nasal turbinates. Taken together, we suggest the recombinant VSV-∆G-spike as a safe, efficacious and protective vaccine against SARS-CoV-2.

AB - The COVID-19 pandemic caused by SARS-CoV-2 imposes an urgent need for rapid development of an efficient and cost-effective vaccine, suitable for mass immunization. Here, we show the development of a replication competent recombinant VSV-∆G-spike vaccine, in which the glycoprotein of VSV is replaced by the spike protein of SARS-CoV-2. In-vitro characterization of this vaccine indicates the expression and presentation of the spike protein on the viral membrane with antigenic similarity to SARS-CoV-2. A golden Syrian hamster in-vivo model for COVID-19 is implemented. We show that a single-dose vaccination results in a rapid and potent induction of SARS-CoV-2 neutralizing antibodies. Importantly, vaccination protects hamsters against SARS-CoV-2 challenge, as demonstrated by the abrogation of body weight loss, and alleviation of the extensive tissue damage and viral loads in lungs and nasal turbinates. Taken together, we suggest the recombinant VSV-∆G-spike as a safe, efficacious and protective vaccine against SARS-CoV-2.

UR - https://www.scopus.com/pages/publications/85097621373

U2 - 10.1038/s41467-020-20228-7

DO - 10.1038/s41467-020-20228-7

M3 - Article

C2 - 33328475

AN - SCOPUS:85097621373

SN - 2041-1723

VL - 11

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 6402

ER -

A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge

Abstract

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this